Cumulus Neuroscience
PrivateLast Round
VC Round
Jul 8, 2025
Est. Valuation
$7.65M
Total Funding Raised
$18.86M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Cumulus Neuroscience operates in Healthcare & Life Sciences and is based in Belfast. Its latest recorded funding round was a VC Round in July 2025.
Cumulus Neuroscience is a health technology company that provides an AI-powered digital biomarker platform with a wearable EEG headset and tablet-based assessments to accelerate clinical trials for central nervous system therapies.
Sector
Healthcare & Life Sciences
Verticals
Clinical Trials, Medical Devices, Healthcare Analytics, Biotechnology, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cumulus Neuroscience Comparables
Compare Cumulus Neuroscience with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cognision | 82% | |
| Beacon Biosignals | 81% | |
| Altoida, Inc. | 79% |
For institutional investors. Book with your work email.
Cumulus Neuroscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Jul 8, 2025 | ||||
| Grant | Jul 11, 2024 | ||||
| Early Funding | Jul 8, 2024 | ||||
| Grant | Mar 20, 2024 | ||||
| Series A | May 4, 2021 | ||||
VC Round | Jul 13, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Cumulus Neuroscience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| ACF Investors | Early Funding, VC Round |
| Par Equity | VC Round |
| SV Health Investors | Seed, Series A |
| Whiterock Finance | Early Funding |
| British Business Bank | Series A, Early Funding |
| Innovate UK | Grant |
| Clarendon Fund Managers | Early Funding, VC Round |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 37% MoM, from 2.3K to 3.1K.
- Jul 20, 2026
Open roles increased to 19, representing 54% of headcount.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 14, 2026
Cumulus Neuroscience Limited co-presents a cross-species analysis using ketamine as a translational probe at the 6th Annual Psychedelic Therapeutics & Drug Development Conference in Louisiana in Feb '26.
- partners_withOct 14, 2026
Cumulus Neuroscience Limited and Transpharmation Ltd. partner to jointly advise biopharma sponsors on preclinical EEG paradigms that align with clinical measurements as assets transition to first-in-human studies.
- attends_eventSep 16, 2026
Cumulus Neuroscience Limited presented three posters at the International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference in Pennsylvania on Sep 16th '26, including interim data on remote brain monitoring and digital cognitive assessment.
For institutional investors. Book with your work email.
Cumulus Neuroscience Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Cumulus Neuroscience's valuation, stock price, and market status.
Is Cumulus Neuroscience a public or private company?
Cumulus Neuroscience is a private company.
What is the current stock price of Cumulus Neuroscience?
Cumulus Neuroscience is a private company, so its shares have no public market price. Caplight tracks Cumulus Neuroscience's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cumulus Neuroscience worth (valuation)?
Cumulus Neuroscience's valuation is estimated at $7.7M based on funding round data.
Can I buy Cumulus Neuroscience stock?
Cumulus Neuroscience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cumulus Neuroscience's last funding round?
Cumulus Neuroscience's most recent funding round was VC Round on July 8, 2025.
Who are the main investors in Cumulus Neuroscience?
Key investors in Cumulus Neuroscience include Par Equity, SV Health Investors, Whiterock Finance.
Will Cumulus Neuroscience IPO soon?
No public IPO plans have been announced for Cumulus Neuroscience.
How can I track Cumulus Neuroscience secondary market activity?
Caplight tracks bids, offers, and trades in Cumulus Neuroscience's shares on secondary markets.